Drug Database
Back to search

France· FR:60661547

NEMLUVIO 30 mg, poudre et solvant pour solution injectable en stylo prérempli

A nemolizumab product containing némolizumab, registered in France by GALDERMA INTERNATIONAL, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC D11AH12

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedNEMLUVIO 30 mg, poudre et solvant pou…ATCD11AH12REGISTER NO.FR:60661547PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about némolizumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Nemolizumab is registered in 14 of 19 countries.

Countries holding a registration under ATC D11AH12 (nemolizumab), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose
Search nemolizumab products by name

Nemolizumab · ATC D11AH12

14 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of nemolizumab costs, country by country.

Normalised to the WHO defined daily dose (0.8 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Nemolizumab · price per daily dose (0.8 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$67.16
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
NÉMOLIZUMAB
Manufacturer
GALDERMA INTERNATIONAL
Country
France (FR)
ATC code
D11AH12
ATC class
Nemolizumab
Defined daily dose
0.8 mg, P
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400930315309
    1 cartouche à double chambre en verre en stylo pré-rempli de 30 mg de poudre et de 0,49 mL de solvant
    EUR 2.01

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Nemolizumab in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nemolizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Nemluvio
  • Liechtenstein · Nemluvio
  • Norway · Nemluvio

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/66be5373-7805-452b-b20d-382f12413a81
GET /v1/drugs/66be5373-7805-452b-b20d-382f12413a81?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "60661547",
  "date_amm": "2025-02-12",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/24/1901",
  "substance": "NÉMOLIZUMAB",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "poudre et  solvant pour solution injectable",
  "voies_administration": "sous-cutanée",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Oui"
}
API referenceMCP serverPlans

See everything about nemolizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console